Experience with Hormonal Therapy in Advanced Epithelial Ovarian Cancer

References

• Boring C C, Squires T S, Tong T. Cancer Statistics 1991. CA 1991; 41: 19–36
   Google Scholar
• FIGO Cancer Committee. Annual report on results of treatment in gynecological Cancer. Stockholm. Int F Gynecol Obstet 1991; 36: 238–77, (Suppl)
   Google Scholar
• Neijt J P. The place of combination chemotherapy in the treatment of advanced ovarian cancer. Proc. of the 17th Study Group of the Royal College of Obstet. Gynaecol. in conjenction with the H. Harris Memorial Trust. Chameleon Press, London 1987; 329–41
   Google Scholar
• Copeland L J, Gershenson D M. Ovarian cancer recurrences in patients with no macroscopic tumor at second‐look laparotomy. Obstet Gynecol 1986; 68: 873–4
   PubMedGoogle Scholar
• Greenwood A W. Controlled environments and cancer incidence in the domestic fowl. Racial and geographical factors in tumour incidence, A Shites. University Press, Edinburgh 1967; 242–7
   Google Scholar
• Greene M H, Clark J W, Blayney D W. The epidemiology of ovarian cancer. Semin Oncol 1984; 11: 209–26
   PubMed Web of Science ®Google Scholar
• Mishell S R, Jr. Non‐contraceptive health benefits of oral steroidal contraceptives. Am J Obstet Gynecol 1982; 142: 809–16
   PubMed Web of Science ®Google Scholar
• Kuhnel R, De Graaf J, Rao B R, Stolk J G. Androgen receptor predominance in human ovarian carcinoma. J Steroid Biochem 1987; 26: 393–7
   PubMedGoogle Scholar
• Kuhnel R, Delemarre J M F, Rao B R, Stolk J G. Correlation of aromatase activity and steroid receptors in human ovarian carcinoma. Anticancer Res 1986; 6: 889–92
   PubMedGoogle Scholar
• Kammerman S, Demopoulos R I, Raphael C, Ross J. Gonadotropic hormone binding to human ovarian tumors. Hum Pathol 1981; 12: 886–90
   PubMed Web of Science ®Google Scholar
• Rajaniemi H, Kauppila A, Ronnberg L, Selander K, Pystynen P. LH(hCG) receptor in benign and malignant tumors of human ovary. Acta Obstet Gynecol Scand 1981; 101: 83–6, (Suppl)
   Google Scholar
• Emons G, Sturm R, Brack C, Knuppen R, Oberheuser F. GnRH‐binding sites in human epithelial ovarian carcinoma. J Steroid Biochem 1987; 28: 162S, (Suppl)
   Google Scholar
• Vermorken J B, van der Burg M E L, Mangioni C, . Ovarian cancer and its response to endocrine treatment. Endocrine‐related tumours, E Engelsman, H J de Koning Cans, et al. Facts and controversies. Update‐Siebert Pub. 1987; 233–9
   Google Scholar
• Thigpen J T, Vance R B, Balducci L, Khansur T. New drugs and experimental approaches in ovarian cancer treatment. Semin Oncol 1984; 11: 314–26
   PubMedGoogle Scholar
• Slotman B J. Rationale for the use of endocrine therapy in ovarian cancer. (Dissertation). Free University Amsterdam, Amsterdam 1990
   Google Scholar
• World Health Organization (WHO). WHO handbook for reporting results of cancer treatment. WHO Offset Publication 48, WHO, Geneva
   Google Scholar
• Emons G, Pahwa G S, Brack C, Sturm R, Oberheuser F, Knuppen R. Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol 1989; 25: 215–21
   PubMedGoogle Scholar
• Sevelda P. Die kombinierte Chemo‐Hormontherapie beim fortgeschrittenen Ovarialkarzinom‐theoretische, experimentelle Grundlagen und klinische Ergebnisse. Wien Klin Wochenschr 1990; 183: 3–29, (Suppl)
   Google Scholar
• Bizzi A, Codegoni A M, Landoni F, et al. Steroid receptors in epithelial ovarian carcinoma: relation to clinical parameters and survival. Cancer Res 1988; 48: 6222–6
   PubMedGoogle Scholar
• From G L, Freedman R S, Fritsche H A, Atkinson E N, Scott W. Sequentially administered ethinyl estradiol and medroxyprogesterone acetate in the treatment of refractory epithelial ovarian carcinoma in patients with positive estrogen receptors. Cancer 1991; 68: 1885–9
   PubMedGoogle Scholar
• O'Brien T J, Hernandez W, Jernstrom P J, Seymour D B, Morrow C P, Sykes J A. Modulation of protein expression in endometrial adenocarcinoma cells by in vitro exposure to estradiol and progesterone. Am J Obstet Gynecol 1981; 139: 67–72
   PubMedGoogle Scholar
• Malkasian G D, Jr, Decker D G, Jorgenson E D, Edmunson H. Medroxyprogesterone acetate for the treatment of metastatic and recurrent ovarian carcinoma. Cancer Treat Rep 1977; 61: 913
   PubMedGoogle Scholar
• Slayton R E, Pegano M, Creech R H. Progestin therapy for advanced ovarian cancer. A phase II Eastern Cooperative Oncology Group trial. Cancer Treat Rep 1981; 65: 895
   PubMedGoogle Scholar
• Mangioni C, Franceschi S, La Vecchia C, D'Incalci M. Highdose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first‐ or second‐line chemotherapy. Gynecol Oncol 1981; 12: 314–8
   PubMedGoogle Scholar
• Aabo K, Pedersen A G, Hald I, Dombernowsky P. High dose medroxyprogesterone acetate (MPA) in advanced chemotherapy resistant ovarian carcinoma: a phase II study. Cancer Treat Rep 1982; 66: 407
   PubMedGoogle Scholar
• Tropé C, Johnsson J E, Sigurdsson K, Simonse E. High‐dose medroxyprogesterone acetate for the treatment of advanced ovarian carcinoma. Cancer Treat Rep 1982; 66: 1441–3
   PubMedGoogle Scholar
• Hamerlynck J VTH, Maskens A P, Mangioni C, et al. Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: an EORTC Gynecological Cancer Cooperative Group study. Gynecol Oncol 1985; 22: 313
   PubMed Web of Science ®Google Scholar
• Landoni F, Epis A, Gorga G, Regallo M, Vassena L, Mangioni C. Hormonal treatment in advanced epithelial ovarian cancer. Anti‐oestrogens in oncology Past, present and prospects, F Panutti. Excerpta Medica, Amsterdam 1985; 262–7
   Google Scholar
• Ahlgren J D, Thomas D, Ellison N, et al. Phase II evaluation of high dose megestrol acetate in advanced refractory ovarian cancer. (Abstract No. C‐481). Proc Am Soc Clin Oncol 1985; 4: 124
   Google Scholar
• Veenhof C H N, van der Burg M E L, van Oosterom A T, et al. High‐dose megestrol acetate in advanced ovarian cancer: A phase II study. (Abstract No. 813). Proc Eur Conf Clin Oncol 1987; 4: 214
   Google Scholar
• Quin M A, Rome R M, Grant P, Planner R S. High‐dose medroxyprogesterone acetate in advanced ovarian cancer. Int J Gynecol Cancer 1991; 1: 239–41
   Google Scholar
• Rendina G M, Donadio C, Giovannini M. Steroid receptors and progestinic therapy in ovarian endometrioid carcinoma. Eur J Gynaecol Oncol 1982; 3: 241–6
   PubMedGoogle Scholar
• Bergquist A, Kullander S, Thorell J. A study of oestrogen and progesterone cytosol receptor concentration in benign and malignant ovarian tumors and review of malignant ovarian tumors treated with medroxyprogesterone acetate. Acta Obstet Gynaecol Scand 1981; 101: 75, (Suppl)
   Google Scholar
• Geisler H. The use of high‐dose megestrol acetate in the treatment of ovarian cancer. Semin Oncol 1985; 11: 20
   Google Scholar
• Schwartz P E, Keating G, MacLusky N, Naftolin F, Eisenfeld A. Tamoxifen therapy for advanced ovarian cancer. Obstet Gynecol 1982; 59: 583–8
   PubMed Web of Science ®Google Scholar
• Shirey D R, Kavanagh J J, Gershenson D M, Freedman R S, Copeland L J, Jones L A. Tamoxifen therapy of epithelial ovarian cancer. Obstet Gynecol 1985; 66: 575–8
   PubMed Web of Science ®Google Scholar
• Slevin M L, Harvey V J, Osborne R J, Shepherd J H, Williams C J, Mead G M. A phase II study of tamoxifen in ovarian cancer. Eur J Cancer Clin Oncol 1986; 22: 309–12
   PubMedGoogle Scholar
• Beecham J, Blessing J, Creasman W, Hatch K. The role of tamoxifen as second line therapy in advanced ovarian cancers evaluated for receptor status and tumor grade, Proc Int Gyn Cancer Soc 1987; 1: 117
   Google Scholar
• Weiner S A, Alberts D S, Surwit E A, Davis J, Grosso D. Tamoxifen therapy in recurrent epithelial ovarian carcinoma. Gynecol Oncol 1987; 27: 208–13
   PubMed Web of Science ®Google Scholar
• Kavanagh J J, Wharton J T, Roberts W S. Androgen therapy in the treatment of refractory epithelial ovarian cancer. Cancer Treat Rep 1987; 71: 537–8
   PubMedGoogle Scholar
• Rothschild N, Gray R, Smith L, Matelski H, Ahlgren J. Phase II study of aminoglutethimide in advanced ovarian cancer. Proc Am Soc Clin Oncol 1987; 6: 115
   Google Scholar
• Long R T L, Evans A M. Diethylstilboestrol as a chemotherapeutic agent for ovarian cancer. Mo Med 1963; 60: 1125–7
   PubMedGoogle Scholar
• Biskind M S, Biskind G R. Development of tumors in the rat ovary after transplantation into the spleen. Proc Soc Exp Biol Med 1944; 55: 176–9
   Google Scholar
• Parmar H, Phillips R H, Rustin G, Lightman S L, Schally A V. Therapy of advanced ovarian cancer with D‐Trp‐6–LH‐RH (decapeptyl) microcapsules. Biomed Pharmacother 1988; 42: 531–8
   PubMed Web of Science ®Google Scholar
• Kavanagh J J, Roberts W, Townsend P, Hewitt S. Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer. J Clin Oncol 1989; 7: 115–8
   PubMed Web of Science ®Google Scholar
• Scambia G, Benedetti Panici P, Greggi S, Bdiocchi G, Perrone L, Mancuso S. Phase II study with an LH‐RH analog in advanced ovarian cancer. J Gynecol Endocrinol 1990; VI(No. 1–4)5–7
   Google Scholar
• Tumulo S, Rao B R, Guastalla J P, van der Burg M E L, Renard J, Vermorken J B. Flutamide (FLU) nelle pazienti con carcinoma avanzato dell ovaio (CAOO). Studio di fase II del gruppo Ginecologico EORTC. Meeting Ital Ass Med Oncol. Annual Tumori. 1990, 76; 4: 140
   Google Scholar
• MacLusky N J, Voit R, Lazo J S, et al. Aromatase activity in human ovarian cancer. Steroids 1987; 50: 423–33
   PubMedGoogle Scholar
• Freedman R S, Saul P B, Edwards C L, et al. Ethinyl estradiol and medroxyprogesterone acetate in patients with epithelial ovarian carcinoma: a phase II study. Cancer Treat Rep 1986; 70: 369–73
   PubMedGoogle Scholar
• Belinson J L, McClure M, Badger G. Randomized trial of megestrol acetate vs megestrol acetate/tamoxifen for the management of progressive or recurrent epithelial ovarian carcinoma. Gynecol Oncol 1987; 28: 151–5
   PubMedGoogle Scholar
• Jakobsen A, Bertelsen K, Sell A. Cyclic hormonal treatment in ovarian cancer. A phase II trial. Eur J Cancer Clin Oncol 1987; 23: 915–6
   PubMedGoogle Scholar